Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-β1b

Cytokine

Volumn 29, Issue 1, 2005, Pages 24-30

  Jensen, Jakob ^a   Krakauer, Martin ^a   Sellebjerg, Finn ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Interferon treatment; Interleukin 12; Multiple sclerosis; T cell immunology; Tumor necrosis factor; Vascular cell adhesion molecule 1

Indexed keywords

ALPHA4 INTEGRIN; INTERFERON BETA SERINE; INTERLEUKIN 12; PROTEIN P40; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MOLECULE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; T LYMPHOCYTE;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; INTEGRIN ALPHA1; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-BETA; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTEIN SUBUNITS; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 9744268908     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2004.09.005     Document Type: Article

References (41)

1. B. Hemmer, J.J. Archelos, and H.-P. Hartung New concepts in the immunopathogenesis of multiple sclerosis Nat Rev Neurosci 3 2002 291 301
2. D.W. Paty, H.-P. Hartung, G.C. Ebers, P. Soelberg-Sorensen, O. Abramsky, and J. Kesselring Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines Eur J Neurol 6 suppl 1 1999 1 35
3. V.W. Yong, S. Chabot, O. Stuve, and G. Williams Interferon beta in the treatment of multiple sclerosis Neurology 51 1998 682 689
4. C.A. Biron Interferons alfa and beta as immune regulators - a new look Immunity 14 2001 661 664
5. K.-P. Wandinger, C.-S. Stürzebecher, B. Belekova, G. Detore, A. Rosenwald, and L.M. Staudt Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes Ann Neurol 50 2001 349 357
6. G. Ristori, C. Montesperelli, C. Gasperini, L. Battistini, G. Borsellino, and C. Buttinelli T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis J Neuroimmunol 99 1999 91 96
7. P.A. Calabresi, L.A. Stone, C.N. Bash, J.A. Frank, and H.F. McFarland Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI Neurology 48 1997 1446 1448
8. L.A. Stone, J.A. Frank, P.S. Albert, C. Bash, M.E. Smith, and H. Maloni The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis Ann Neurol 37 1995 611 619
9. R.A. Rudick, D.L. Cookfair, N.A. Simonian, R.M. Ransohoff, J.R. Richert, and L.D. Jacobs Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNb-1a) for relapsing multiple sclerosis J Neuroimmunol 93 1999 8 14
10. T.L. Sørensen Sellebjerg F Interferon-beta treatment modulates CXC chemokine receptor (CXCR3) expression pattern in multiple sclerosis Mult Scler 8 2002 104 107
11. P.A. Calabresi, C.M. Pelfrey, L.R. Tranquill, H. Maloni, and H.F. McFarland VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta Neurology 49 1997 1111 1116
12. P.A. Muraro, T. Leist, B. Bilekova, and H.F. McFarland VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis J Neuroimmunol 111 2000 186 194
13. P.A. Calabresi, L.R. Tranquill, J.M. Dambrosia, L.A. Stone, H. Maloni, and C.N. Bash Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b Ann Neurol 41 1997 669 674
14. B.A. Kallmann, V. Hummel, T. Lindellaub, K. Ruprecht, K.V. Toyka, and P. Rieckmann Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1 Brain 123 2000 687 697
15. C.M. Poser, D.W. Paty, L. Scheinberg, W.I. McDonald, F.A. Davis, and G.C. Ebers New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 1983 227 231
16. J.F. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
17. L.M. Ossege, E. Sindern, T. Patzold, and J.-P. Malin Immunomodulatory effects of interferon-beta-1b in vivo: induction of the expression of transforming growth factor-beta1 and its receptor type II J Neuroimmunol 91 1998 73 81
18. D. Matusevicius, P. Kivisäkk, V. Navikas, W.-Z. Tian, M. Söderström, and S. Fredrikson Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis Eur J Neurol 5 1998 265 275
19. E. Corsini, M. Gelati, A. Dufour, G. Massa, A. Nespolo, and E. Ciusani Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study J Neuroimmunol 79 1997 76 83
20. M. Kilinc, and I. Saatci-Cekirge Karabudak R Serial analysis of soluble intercellular adhesion molecule-1 level in relapsing-remitting multiple sclerosis patients during IFN-beta1b treatment J Interferon Cytokine Res 23 2003 127 133
21. M. Trojano, C. Avolio, G.M. Liuzzi, M. Ruggieri, G. Defazio, and M. Liguori Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS Neurology 53 1999 1402 1408
22. M.E. Duddy, M.A. Armstrong, A.D. Crockard, and S.A. Hawkins Changes in plasma cytokines induced by interferon-beta1a treatment in patients with multiple sclerosis J Neuroimmunol 101 1999 98 109
23. D. Bahner, C. Klucke, B. Kitze, E. Elitok, T. Bogumil, and A. Dressel Interferon-beta-1b increases serum interleukin-12 p40 levles in primary progressive multiple sclerosis patients Neurosci Lett 326 2002 125 128
24. M.H.G. Rep, H.M. Schrijver, T. van Lopik, R.Q. Hintzen, M.T.L. Roos, and H.J. AdŠr Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients J Neuroimmunol 96 1999 92 100
25. J. Losy Michalowska-Wender G In vivo effect of interferon-beta 1a on interleukin-12 and TGF-beta1 cytokines in patients with relapsing-remitting multiple sclerosis Acta Neurol Scand 106 2002 44 46
26. M.A. Barrau, X. Montalban, I. Saez-Torres, L. Brieva, N. Barbera, and E.M. Martinez-Cacarez CD4+CD45R0CD49d high cells are involved in the pathogenesis of relapsing-remitting multiple sclerosis J Neuroimmunol 111 2000 215 223
27. K.M. Murphy, and S.L. Reiner The lineage decisions of helper T cells Nat Rev Immunol 2 2002 933 944
28. G.L. Costa, M.R. Sandora, A. Nakajima, E.V. Nguyen, C. Taylor-Edwards, and A.J. Slavin Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit J Immunol 167 2001 2379 2387
29. B. Oppmann, R. Lesley, B. Blom, J.C. Timans, Y. Xu, and B. Hunte Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 Immunity 13 2000 715 725
30. D.J. Cua, J. Sherlock, Y. Chen, C.A. Murphy, B. Joyce, and B. Seymour Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 421 2003 744 748
31. P.V. Byskosh, and A.T. Reder Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis Mult Scler 1 1996 262 269
32. P. Sarchielli, A. Critelli, L. Greco, E. Sokola, A. Floridi, and V. Gallai Expression of TNF-alfa mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1a Cytokine 14 2001 294 298
33. A. Gayo, L. Mozo, A. Suarez, A. Tunon, C. Lahoz, and C. Gutierrez Interferon beta-1b treatment modulates TNFalfa and IFNgamma spontaneous gene expression in MS Neurology 52 1999 1764 1770
34. V. Özenci, M. Kouwenhoven, N. Teleshova, M. Pashenkov, S. Fredrikson, and H. Link Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta J Neuroimmunol 108 2000 236 343
35. A.H.H. van Boxel-Dezaire, S.C.J. van Trigt-Hoff, J. Killestein, H.M. Schrijver, J.C. van Howelingen, and C.H. Polman Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment? Ann Neurol 48 2000 313 322
36. B.W. van Oosten, F. Barkhof, L. Truyen, J.B. Boringa, F.W. Bertelsmann, and B.M.E. von Blomberg Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 Neurology 47 1996 1531 1534
37. The Lenercept Multiple Sclerosis Study Group, and The University of British Columbia MS/MRI Analysis Group TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study Neurology 53 1999 457 465
38. L. Probert, H.P. Eugster, K. Akassaglou, J. Bauer, K. Frei, and H. Lassmann TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease Brain 123 2000 2005 2019
39. P.A. Calabresi, A. Prat, K. Biernacki, J. Rollins, and J.P. Antel T lymphocytes conditioned with interferon beta induce membrane and soluble VCAM on human brain endothelial cells J Neuroimmunol 115 2001 161 167
40. N. Tubridy, P.O. Behan, R. Capildeo, A. Chaudhuri, R. Forbes, and C.P. Hawkins The effect of anti-alfa4 integrin antibody on brain lesion activity in MS Neurology 53 1999 466 472
41. D.H. Miller, O.A. Khan, W.A. Sheremata, L.D. Blumhardt, G.P. Rice, and M.A. Libonati A controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 348 2003 15 23